Score Overview
Explore the 2021 public Archive ranking →
Where Lexicon Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- LXRX
2011: 99.7% · 2021: 56.5% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 1.88 | — |
1 Year2025-09-29 | $ 1.39 | 35.25% |
5 Years2021-09-29 | $ 4.91 | -61.71% |
10 Years2016-09-29 | $ 17.90 | -89.50% |
20 Years2006-09-29 | $ 26.39 | -92.88% |
All Time2000-04-07 | $ 131.25 | -98.57% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2000-04-07 |
|---|---|---|---|---|---|---|
| Price | $ 1.88 | $ 1.39 | $ 4.91 | $ 17.90 | $ 26.39 | $ 131.25 |
| Return | — | 35.25% | -61.71% | -89.50% | -92.88% | -98.57% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 41M | -$ 61M | $ 190M |
| 2025 | $ 49M | -$ 50M | $ 96M |
| 2024 | $ 31M | -$ 200M | $ 237M |
| 2023 | $ 1M | -$ 177M | $ 170M |
| 2022 | -$ 101M | $ 138M | |
| 2021 | -$ 87M | $ 86M | |
| 2020 | $ 23M | -$ 58M | $ 152M |
| 2019 | $ 322M | $ 130M | $ 271M |
| 2018 | $ 63M | -$ 120M | $ 160M |
| 2017 | $ 90M | -$ 129M | $ 310M |
| 2016 | $ 83M | -$ 141M | $ 346M |
| 2015 | $ 130M | -$ 4M | $ 521M |
| 2014 | $ 22M | -$ 100M | $ 339M |
| 2013 | $ 2M | -$ 104M | $ 129M |
| 2012 | $ 1M | -$ 110M | $ 223M |
| 2011 | $ 1M | -$ 116M | $ 281M |
| 2010 | $ 4M | -$ 101M | $ 211M |
| 2009 | $ 10M | -$ 82M | $ 162M |
| 2008 | $ 32M | -$ 76M | $ 103M |
| 2007 | $ 50M | -$ 58M | $ 258M |
| 2006 | $ 72M | -$ 54M | $ 79M |
| 2005 | $ 75M | -$ 36M | $ 99M |
| 2004 | $ 61M | -$ 47M | $ 87M |
| 2003 | $ 42M | -$ 64M | $ 104M |
| 2002 | $ 35M | -$ 59M | $ 93M |
| 2001 | $ 305M | -$ 35M | $ 156M |
| IPO2000 | $ 14M | -$ 25M | $ 202M |
Lexicon Pharmaceuticals Inc fundamental performance
Between 2015 and 2025, revenue declined from $ 130M to $ 49M and net income went from -$ 4M to -$ 50M. Revenue increased in 6 of those 10 years; net income in 4.
Across Lexicon Pharmaceuticals Inc's full reported history, from 2000 to 2025, revenue grew from $ 14M to $ 49M and net income went from -$ 25M to -$ 50M. Revenue increased in 48% of the years measured; net income in 38%.
Lexicon Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.
Membership
Continue LXRX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
